Tri Locum Partners LP reported 19 holdings worth US$813M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Tri Locum Partners LP reported 19 holdings worth US$813M as of Jun 30, 2026. Largest: Johnson & Johnson, Vertex Pharmaceuticals Incorporated and Eli Lilly And Company. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 19
- Value as reported
- US$813M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Johnson & Johnson | 425K | US$108M | 13.3% |
| Vertex Pharmaceuticals Incorporated | 202K | US$100M | 12.3% |
| Eli Lilly And Company | 76,532 | US$91.8M | 11.3% |
| Dexcom, Inc. | 820K | US$55.3M | 6.8% |
| Axsome Therapeutics, Inc. | 219K | US$53.7M | 6.6% |
| Enliven Therapeutics, Inc. | 867K | US$44M | 5.4% |
| Argenx Se | 41,596 | US$38.6M | 4.7% |
| Madrigal Pharmaceuticals, Inc. | 68,273 | US$36.7M | 4.5% |
| Revolution Medicines, Inc. | 152K | US$28.4M | 3.5% |
| United Therapeutics Corporation | 47,026 | US$25.5M | 3.1% |
| Teva Pharmaceutical Industries Limited | 747K | US$25.3M | 3.1% |
| Tarsus Pharmaceuticals, Inc. | 328K | US$20.7M | 2.5% |
| Intuitive Surgical, Inc. | 47,983 | US$19.1M | 2.3% |
| Cytokinetics, Incorporated | 194K | US$16.5M | 2.0% |
| Dianthus Therapeutics, Inc. | 121K | US$11.8M | 1.4% |
| Beta Bionics, Inc. | 493K | US$7.73M | 0.95% |
| Definium Therapeutics, Inc. | 163K | US$7.67M | 0.94% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
| Nuvalent, Inc. | 0 | US$0 | 0.00% |
| Thermo Fisher Scientific Inc | 0 | US$0 | 0.00% |